FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634
Citation: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634 Parties: OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY v GENERIC HEALTH PTY LTD;
GENERIC HEALTH PTY LTD v OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY File number(s): NSD 121 of 2012 Judge(s): YATES J Date of judgment: 29 June 2015 Catchwords: PATENTS – standard patent for the use of a carbostyril compound for the production of a medicament having certain features and a method for treating a patient involving the use of the carbostyril compound – where the carbostyril compound (aripiprazole) is claimed to be effective in treating disorders of the central nervous system associated with the 5‑HT1A receptor subtype – treatment of cognitive impairment in schizophrenia
PATENTS – Swiss type claims – discussion of derivation of this form of claim – whether Swiss type claim should be characterised as a method or process
PATENTS – the person skilled in the art considered as a team – whether the team can be differently constituted depending on the patent question involved
PATENTS – infringement – Swiss type claim – whether claim can be infringed by exploitation in the patent area of a medicament manufactured outside the patent area – discussion of Saccharin doctrine
PATENTS – infringement – application of s 117(2)(b) of the Patents Act 1900 (Cth) to a method of treating the human body with a pharmaceutical product
PATENTS – validity – novelty
PATENTS – validity – manner of new manufacture – whether an invention is disclosed on the face of the specification
PATENTS – validity – inventive step – whether invention as claimed is obvious – whether person skilled in the art could be reasonably expected to have ascertained, understood and regarded as relevant certain prior art documents – whether certain sources of information would have been combined by the person skilled in the art
PATENTS – validity – utility
PATENTS – validity – sufficiency and best method
PATENTS – validity – clarity and definition
PATENTS – validity – fair basis
PATENTS – standing to sue for infringement – whether second applicant an exclusive licensee
Legislation: Act revising the Convention on the Grant of European Patents of 29 November 2000 (entered into force on 13 December 2007)
Convention on the Grant of European Patents, opened for signature 5 October 1973, 1065 UNTS 199 (entered into force 7 October 1977)
Patents Act 1990 (Cth) ss 7, 18, 40, 117
Patents Act 1977 (UK)Cases cited: ABBOTT RESPIRATORY/Dosage Regime (G02/08) [2010] EPOR 26
Actavis UK Ltd v Janssen Pharmaceutica NV [2008] FSR 35
Actavis UK Ltd v Merck & Co Inc [2009] 1 WLR 1186
Aktiebolaget Hässle v Alphapharm Pty Limited (2002) 212 CLR 411
Alphapharm Pty Ltd v H Lundbeck A/S (2008) 76 IPR 618
AMERICAN CYANAMID/Melamine Derivatives (T279/93) [1999] EPOR 88
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 2) (2012)
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2015] FCA 634
- Decision Date
CaseChat Overview and Summary
The court had to determine several critical legal issues, including the interpretation of Swiss-type claims, the constitution of the person skilled in the art, and the applicability of the Saccharin doctrine to Swiss-type claims. It also needed to assess whether the patent met the requirements of novelty, inventive step, utility, and sufficiency, as well as whether the person skilled in the art could reasonably be expected to have combined certain prior art documents. Additionally, the court examined whether the second applicant had standing to sue for infringement, given their status as an exclusive licensee.
The court found that the patent claims were not properly characterised as Swiss-type claims and were instead method claims. It held that the team of the person skilled in the art should not be differently constituted based on the specific patent question. The court also determined that the Swiss-type claim could not be infringed by exploiting a medicament manufactured outside the patent area, consistent with the Saccharin doctrine. Regarding validity, the court found that the patent met the requirements of novelty, inventive step, utility, and sufficiency. The court concluded that the second applicant had standing to sue for infringement as an exclusive licensee.
The court ordered the parties to bring in draft orders by a specified date, and if they could not agree on costs, to provide written submissions and a draft order for the court’s consideration.
Orders
Orders of the court
1. The parties are to bring in draft orders giving effect to these reasons by 4.00 pm on 13 July 2015.
2. If the parties are unable to agree on the question of costs, they are to provide short written submissions (not exceeding three pages) on that question, together with a draft of the order that is sought.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi